1Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2Gastrointestinal Cancer Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran
4Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran
5Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Copyright © 2019 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
The authors have no conflicts of interest associated with the material presented in this paper.
Authors [Ref] | Area of study | Publication year | Median survival time (mo) | Five-year overall survival rate (%) |
HR (95% CI) |
Type of model used | ||
---|---|---|---|---|---|---|---|---|
Sex | Age (y) | Type of lung cancer | ||||||
Abazari et al. [1] | Iran | 2015 | 4.8 | - | M/F: 1.14 (0.85, 1.54) | 60-70/<60: 1.37 (1.02, 1.83) | SCLC/NSCLC: 1.04 (0.66, 1.66) | Cox regression |
Zhang et al. [6] | China | 2017 | - | 35.2 | - | - | - | - |
Prim et al. [8] | Spain | 2010 | 11.1 | 8.9 | - | - | - | - |
Svensson et al. [9] | Sweden | 2013 | - | 13.6 | M/F: 1.21 (1.06, 1.37) | 60-69/<60:1.07 (0.89, 1.30) | - | Cox regression |
Biswas et al. [10] | USA | 2014 | - | - | M/F: 1.10 (1.01, 1.10) | 51-70/25-50:1.40 (1.20, 1.80) | - | Cox regression |
Ball et al. [11] | Australia | 2013 | 6.1 | - | - | - | - | - |
Zahir et al. [12] | Iran | 2012 | 8.5 | - | - | - | - | - |
Grivaux et al. [13] | France | 2009 | 7.0 | 10.4 | - | - | - | - |
Variables | Univariate exponential regression |
Multivariate exponential regression |
||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age | 1.03 (1.01, 1.05) | 0.002 | 1.03 (1.01, 1.05) | <0.001 |
Sex | 0.52 (0.31, 0.86) | 0.011 | 0.56 (0.33, 0.93) | 0.025 |
Type of lung cancer | 2.59 (1.55, 4.33) | <0.001 | 2.91 (1.71, 4.95) | <0.001 |
Authors [Ref] | Area of study | Publication year | Median survival time (mo) | Five-year overall survival rate (%) | HR (95% CI) |
Type of model used | ||
---|---|---|---|---|---|---|---|---|
Sex | Age (y) | Type of lung cancer | ||||||
Abazari et al. [1] | Iran | 2015 | 4.8 | - | M/F: 1.14 (0.85, 1.54) | 60-70/<60: 1.37 (1.02, 1.83) | SCLC/NSCLC: 1.04 (0.66, 1.66) | Cox regression |
Zhang et al. [6] | China | 2017 | - | 35.2 | - | - | - | - |
Prim et al. [8] | Spain | 2010 | 11.1 | 8.9 | - | - | - | - |
Svensson et al. [9] | Sweden | 2013 | - | 13.6 | M/F: 1.21 (1.06, 1.37) | 60-69/<60:1.07 (0.89, 1.30) | - | Cox regression |
Biswas et al. [10] | USA | 2014 | - | - | M/F: 1.10 (1.01, 1.10) | 51-70/25-50:1.40 (1.20, 1.80) | - | Cox regression |
Ball et al. [11] | Australia | 2013 | 6.1 | - | - | - | - | - |
Zahir et al. [12] | Iran | 2012 | 8.5 | - | - | - | - | - |
Grivaux et al. [13] | France | 2009 | 7.0 | 10.4 | - | - | - | - |
HR, hazard ratio; CI, confidence interval.
HR, hazard ratio; CI, confidence interval; SCLC, small cell lung carcinoma; NSCLC, non-small cell lung carcinoma; M, male; F, female.